

Invoice Number Date

: 11728227 : 28-NOV-24

Page

:1 /1

INVOICE

MAINE DEP RAY BUILDING 17 STATE HOUSE STATION AUGUSTA ME 04333 **United States**

Customer Number Currency Payment Term **Due Date**

3229981 USD

Net Due in 30 Days 28-DEC-24

SGS Order No.

Purchase Order Ref.

1452410

CTMV #20240605-0026; Freshwater

SWAT

Customer Reference General Description

4424-DR - Attention: Tom Danielson

PDF Invoice to: thomas,i,danielson@maine.gov; CC: James,Stahlnecker@maine.gov

Item	Description		Quantity	UoM	Unit Price	Net Amount	Amount
40518	PCBs		4	Ea	1,017.00	4,068.00	4,068.00
	Actual Execution End-Date Object Name / Description	28-NOV-2024 PCB Congener: Samples L41941- 12-15					
61417	Per- and Polyfluoroalkyl Substan	nces (PFAS)	24	Ea	489.00	11,736.00	11,736.00
	Actual Execution End-Date Object Name / Description	28-NOV-2024 PFAS: Samples L42148- 1-24					
37385	Sample Preparation		28	Ea	41.00	1,148.00	1,148.00
	Actual Execution End-Date Object Name / Description	28-NOV-2024 Homogenization: Samples L41941 -12-15,	L42148 -1-24				
40574	Miscellaneous Costs		28	Ea	11.00	308.00	308.00
	Actual Execution End-Date Object Name / Description	28-NOV-2024 Environment and Disposal Fee - L41941 -12-15, L42148 -1-24					
					Net Amount U Sum of Tax U		17,260.00 0.00
				Tota	I Amount US	SD 1	7,260.00

11728227 28-NOV-24 3229981

AXYS ANALYTICAL SERVICES LTD IS NOW PART OF SGS, THE WORLD'S LEADING INSPECTION, VERIFICATION, TESTING AND CERTIFICATION COMPANY.

SGS AXYS Analytical Services Ltd | Industries & Environment 2045 Mills Road West Sidney, BC, V8L 5X2 Canada t: (250) 655-5800 f: (250) 655-5811

SGS Tax ID GST# R119480622 EIN#98-0164200

Member of the SGS Group



USD Payment Remittance information:

PLEASE INCLUDE INVOICE NUMBERS WITH PAYMENT DETAIL

ACH/EFT/WIRE Payment

Beneficiary Bank: Citibank

Branch Address: 1 Penns Way. New Castle, DE 19720

Branch: Delaware 920

Beneficiary Name: SGS Canada

SWIFT: CITIUS33

ABA/Routing: 031100209

Account: 39086139

Send remittance details by fax or email to 905-364-0343 or ca.argroup@sgs.com

TO PAY BY CREDIT/DEBIT CARD OR ACH USING OUR ONLINE PAYMENT PORTAL:

https://try.sgs.com/nam-en/einvoiceconnect

BATCH SUMMARY

Batch ID:	WG91289	Date:	25-Oct-2024			
Analysis Type:	PCB Congener	Matrix	Type: Tissue			
BATCH MAKEUP						
Contract: Samples:	4424	Blank:	WG91289-101			
L41941-12 L41941-13 L41941-14 L41941-15	941-13 KSD-SMB-C2(6,7,8,9,10)-2024 941-14 KNW-SMB-C1(1,2,3,4,5)-2024					
		Referen	nce or Spike: WG91289-102			
		Duplica	te:			

Comments:

- 1. Data are considered final.
- 2. Data are not blank corrected. Blank data should be taken into consideration when evaluating sample data.
- 3. Blank data should be evaluated against specifications using the same blank sample size as the size of the client samples.
- 4. The temperature of the samples upon receipt was 20.2C, exceeding the method requirement of <4°C.

BATCH SUMMARY

Batch ID:	WG91718	Date: 14-Nov-2024
Analysis Typ	pe: Per- and Polyfluoroalkyl Substances (PFAS)	Matrix Type: Tissue
	BATCH MAKEUF	
Contract: Samples:	4424	Blank: WG91718-101
L42148-1	ARB2-WCF-1	
L42148-2	ARB2-SMB-C1(1,2,3,4,5)-2024	
L42148-3	ARB2-SMB-C2(6,7,8,9,10)-2024	
L42148-4	ARB2-SMB-C3(11,12,13,14,15)-2024	
L42148-5	ARB2-SMB-C4(16,17,18,19,20)-2024	
L42148-6	ART-SMB-C1(1,2,3,4,5)-2024	Reference or Spike:
L42148-7	ART-SMB-C2(6,7,8,9,10)-2024	WG91718-102
L42148-8	MAB0-BKT-C1(1,2,3,4,5)-2024	WG91718-103
L42148-9	MAB0-BKT-C2(6,7,8,9,10)-2024	
L42148-10	MAB2-BKT-C1(1,2,3)-2024	
L42148-11	MAB2-BKT-C2(4,5,6)-2024	
_42148-12	MAB2-EEL-C1(1,2,3)-2024	
L42148-13	MAB2-EEL-C2(4,5,6)-2024	
L42148-14	MAB2-EEL-C3(7,8,9)-2024	Duplicate:
L42148-15	MAB2-EEL-C4(10,11,12)-2024	WG91718-104
L42148-16	MEB-BLC-C1(1,2,3)-2024	
L42148-17	MEB-BLC-C2(4,5,6)-2024	
_42148-18	MEB-BLC-C3(7,8,9)-2024	
L42148-19	MEB-BLC-C4(10,11,12)-2024	
_42148-20	LK5686-LMB-C1(1,2,3,4,5)-2024	

Comments:

- Data are considered final.
 Data are not blank corrected. Blank data should be taken into consideration when evaluating sample data.
- 3. For the laboratory procedural blank sample (SGS AXYS ID: WG91718-101), the target analyte PFUNA was detected at concentration above the reporting limit but below the SGS AXYS method limit, and NETFOSE was detected above SGS AXYS method limit. Where the same compound was detected in another sample, the result was flagged with a 'B'. Data are not blank corrected and should be taken into consideration during data review and
- 4. In the instrument sensitivity check (C-Cal, filename: FC4G_295 S:13) and in the continuing calibration verifications (filename: FC4G_295 S:20, 37), the surrogate compounds D7-NME-FOSE and D9-N-ETFOSE were observed above method specifications. Given that the corresponding analytes met method criteria, data are not considered affected.
- 5. For the QC and some client samples, where the percent recovery for a surrogate compound was below 5% but still above 1%, the result for the detected related target analyte(s) were flagged with a 'K' and should be considered the maximum possible concentration. In all other cases, where the percent recovery for a surrogate compound did not meet the method criteria limit, the result was flagged with a 'V'. As the isotope dilution method of quantification produces data that is recovery corrected, these variances from method criteria were deemed to not affect the quantification of the target analytes. Percent surrogate recoveries are used as general method performance indicator only.
- 6. The presence of the analyte ETFOSE interference was noted in the laboratory procedural blank and some client samples. Wherever this analyte was detected, it has been flagged with a 'K'. The concentration of this analyte should be considered the maximum possible value.

BATCH SUMMARY

Batch ID:	WG91717	Date: 15-Nov-2024				
Analysis Type:	Per- and Polyfluoroalkyl Substances (PFAS)	Matrix Type: Tissue				
BATCH MAKEUP						
Contract: Samples:	4424	<i>Blank:</i> WG91717-101				
L42148-21 L42148-22 L42148-23 L42148-24	SEM-SMB-C1(1,2,3,4,5)-2024 SEM-SMB-C2(6,7,8,9,10)-2024 MEB-BKT-1-2024 MEB-BKT-C1(2,3)-2024					
		Reference or Spike: WG91717-102 WG91717-103				
		Duplicate:				

Comments:

- 1. Data are considered final.
- 2. Data are not blank corrected. Blank data should be taken into consideration when evaluating sample data.
- 3. For the laboratory procedural blank sample (SGS AXYS ID: WG91717-101), the target analytes PFOA and PFUNA were detected at concentrations above the reporting limit but below the SGS AXYS method limit. Where the same compound was detected in another sample, the result was flagged with a 'B'. Data are not blank corrected and should be taken into consideration during data review and interpretation.
- 4. In the instrument sensitivity check (C-Cal, filename: FC4L_309 S:13), the surrogate compounds D5-N-ETFOSA, D3-MEFOSAA and D9-N-ETFOSE were observed outside method specifications. Given that the corresponding analytes met method criteria, data are not considered affected. In addition, PFEESA was observed marginally above (130.5%) the method control limit (130%). As the same analyte was not detected in the client samples, data are not considered to be affected.
- 5. Percent recovery of labeled compounds D5-N-ETFOSA and D9-N-ETFOSE in the continuing calibration (data filename: FC4L_309 S:37) were outside the method control limits. Given that the corresponding analytes met method criteria, data are not considered affected.
- 6. In the OPR and LLOPR (SGS AXYS ID: WG91717-102, -103), N-MEFOSE was observed above the method control limit and is flagged with a 'N'. As this analyte was not detected in the client samples, this is deemed not to have any effect on the sample data. Data are not similarly affected.
- 7. For the QC and some client samples, where the percent recovery for a surrogate compound was below 5% but still above 1%, the result for the detected related target analyte(s) were flagged with a 'K' and should be considered the maximum possible concentration. In all other cases, where the percent recovery for a surrogate compound did not meet the method criteria limit, the result was flagged with a 'V'. As the isotope dilution method of quantification produces data that is recovery corrected, these variances from method criteria were deemed to not affect the quantification of the target analytes. Percent surrogate recoveries are used as general method performance indicator only.